The global market for Cancer Vaccines was valued at US$8.7 Billion in 2024 and is projected to reach US$14.8 Billion by 2030, growing at a CAGR of 9.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
The development and enhancement of cancer vaccines involve intricate biotechnological advancements and significant research investments. Molecular techniques such as gene sequencing and bioinformatics are crucial in identifying tumor-specific antigens and developing vaccines that can target them effectively. Modern biotechnology has also enabled the design of personalized vaccines that are tailored to the unique genetic makeup of an individual’s tumor, thereby increasing the effectiveness of the treatment. Furthermore, innovations such as the use of viral vectors, dendritic cell vaccines, and RNA technology have expanded the potential of therapeutic cancer vaccines. These advances have been supported by a robust clinical trial infrastructure that allows for the rapid assessment and optimization of vaccine formulations and dosing schedules, ensuring that only the most effective treatments reach patients.
The growth in the cancer vaccine market is driven by several factors, including the increasing incidence of cancer worldwide, the rising demand for personalized medicine, and substantial investments in healthcare infrastructure supporting immunotherapy. As cancer remains a leading cause of death globally, governments and healthcare organizations are emphasizing early detection and prevention, which bolsters the market for preventive vaccines. In parallel, the therapeutic cancer vaccine sector benefits from the growing number of cancer patients who require effective treatment after diagnosis. Technological advancements in vaccine development platforms and adjuvant systems continue to enhance the efficacy and safety profiles of cancer vaccines, making them more appealing to both healthcare providers and patients. Additionally, the growing public awareness about the potential of immunotherapy in treating cancer, coupled with increasing healthcare spending in emerging economies, is propelling market growth. Market expansion is further supported by strategic collaborations between biopharmaceutical companies aiming to accelerate the development and commercialization of new vaccines. These drivers ensure the sustained growth of the cancer vaccine industry, reflecting its critical role in modern oncological therapeutics and preventive healthcare.
Key Trends and Drivers
Cancer vaccines represent a significant advancement in oncological medicine, offering potential for both the prevention and treatment of various forms of cancer. These vaccines work by stimulating the immune system to attack cells that display tumor-specific antigens, thereby preventing these cells from developing into full-blown cancers or eradicating existing tumors. Preventative vaccines, such as those developed for human papillomavirus (HPV) which is linked to cervical, anal, and other cancers, have already demonstrated efficacy in reducing cancer risk among vaccinated populations. Therapeutic cancer vaccines, on the other hand, are used to treat existing cancers by strengthening the body's immune response to fight the cancer cells. Several therapeutic vaccines are in clinical trials, targeting a range of cancers including melanoma, prostate, lung, and breast cancers.The development and enhancement of cancer vaccines involve intricate biotechnological advancements and significant research investments. Molecular techniques such as gene sequencing and bioinformatics are crucial in identifying tumor-specific antigens and developing vaccines that can target them effectively. Modern biotechnology has also enabled the design of personalized vaccines that are tailored to the unique genetic makeup of an individual’s tumor, thereby increasing the effectiveness of the treatment. Furthermore, innovations such as the use of viral vectors, dendritic cell vaccines, and RNA technology have expanded the potential of therapeutic cancer vaccines. These advances have been supported by a robust clinical trial infrastructure that allows for the rapid assessment and optimization of vaccine formulations and dosing schedules, ensuring that only the most effective treatments reach patients.
The growth in the cancer vaccine market is driven by several factors, including the increasing incidence of cancer worldwide, the rising demand for personalized medicine, and substantial investments in healthcare infrastructure supporting immunotherapy. As cancer remains a leading cause of death globally, governments and healthcare organizations are emphasizing early detection and prevention, which bolsters the market for preventive vaccines. In parallel, the therapeutic cancer vaccine sector benefits from the growing number of cancer patients who require effective treatment after diagnosis. Technological advancements in vaccine development platforms and adjuvant systems continue to enhance the efficacy and safety profiles of cancer vaccines, making them more appealing to both healthcare providers and patients. Additionally, the growing public awareness about the potential of immunotherapy in treating cancer, coupled with increasing healthcare spending in emerging economies, is propelling market growth. Market expansion is further supported by strategic collaborations between biopharmaceutical companies aiming to accelerate the development and commercialization of new vaccines. These drivers ensure the sustained growth of the cancer vaccine industry, reflecting its critical role in modern oncological therapeutics and preventive healthcare.
Report Scope
The report analyzes the Cancer Vaccines market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments
Vaccine Type (Preventive Vaccine, Therapeutic Vaccine, Other Vaccine Types); Technology (Recombinant Technology, Viral Vector & DNA Technology, Whole-Cell Technology, Other Technologies); Application (Cervical Application, Prostate Application, Bladder Application, Melanoma Application, Other Applications).Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Preventive Vaccine segment, which is expected to reach US$7.6 Billion by 2030 with a CAGR of a 9%. The Therapeutic Vaccine segment is also set to grow at 10% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $2.3 Billion in 2024, and China, forecasted to grow at an impressive 12.8% CAGR to reach $3.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Agenus Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celldex Therapeutics Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Cancer Vaccines Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer Vaccines Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Cancer Vaccines Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 61 major companies featured in this Cancer Vaccines market report include:
- Agenus Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celldex Therapeutics Inc.
- F. Hoffmann-La Roche Ltd
- Genexine Inc.
- Gritstone bio
- ImmunityBio, Inc.
- Immutep Ltd
- ISA Pharmaceuticals B.V.
- Merck & Co. Inc.
- Northwest Biotherapeutics Inc.
- OncBioMune Pharmaceuticals Inc.
- Oncovir Inc.
- Pfizer Inc.
- Sanofi SA
- Serum Institute of India Pvt. Ltd.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agenus Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Celldex Therapeutics Inc.
- F. Hoffmann-La Roche Ltd
- Genexine Inc.
- Gritstone bio
- ImmunityBio, Inc.
- Immutep Ltd
- ISA Pharmaceuticals B.V.
- Merck & Co. Inc.
- Northwest Biotherapeutics Inc.
- OncBioMune Pharmaceuticals Inc.
- Oncovir Inc.
- Pfizer Inc.
- Sanofi SA
- Serum Institute of India Pvt. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 403 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 8.7 Billion |
| Forecasted Market Value ( USD | $ 14.8 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
